论文部分内容阅读
经手术根治、无远处转移(PT_1 _4PN_1 _2M_0)的非小细胞肺癌(NSCLC)139例,对照组215例为良性上皮肿瘤,非上皮肿瘤或炎症性疾病。除了手术后30天内死亡的11例外,以书面形式每6个月向经治医师了解关于患者的复发或死亡情况。于切除原发肿瘤前后即刻行2～4次骨髓穿刺检查,共抽取骨髓液2～10ml。采用针对细胞角蛋白多肽18(CK18)的CK2单抗检测骨髓肿瘤细胞,Ber-EP4单抗免疫组化检测淋巴结的微
There were 139 patients with non-small cell lung cancer (NSCLC) who had undergone surgery, no distant metastasis (PT_1 _4PN_1 _2M_0), and 215 patients in the control group had benign epithelial tumors, non-epithelial neoplasia or inflammatory diseases. With the exception of 11 deaths within 30 days after surgery, the treating physician was informed about the patient’s recurrence or death every 6 months in writing. Immediately before and after removal of the primary tumor, 2 to 4 bone marrow puncture tests were performed, and a total of 2 to 10 ml of bone marrow fluid was collected. Bone marrow tumor cells were detected using a CK2 monoclonal antibody against cytokeratin polypeptide 18 (CK18). Immunohistochemical staining of Ber-EP4 monoclonal antibody was performed to detect lymph node micrometastases.